首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Ossification and increased bone mineral density with zoledronic acid in a patient with lung adenocarcinoma: A case report
【2h】

Ossification and increased bone mineral density with zoledronic acid in a patient with lung adenocarcinoma: A case report

机译:唑来膦酸使肺腺癌患者骨化并增加骨矿物质密度:一例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cases of ossification and increased bone mineral density (BMD) at sites of bone metastasis following zoledronic acid (ZA) treatment have not been reported. The current study presents the case of a 65-year-old patient with lung adenocarcinoma and bone metastases in the lumbar vertebrae and femurs. Ossification and an increase in BMD at the metastatic sites was achieved following treatment with ZA and irradiation of the bone metastatic sites. The patient was able to maintain a normal lifestyle for over two years, despite the bone metastases. Therefore, as treatment with ZA was demonstrated to improve patient quality of life, physicians should consider this treatment strategy, particularly for the treatment of metastasis in weight-bearing bones.
机译:唑来膦酸(ZA)治疗后骨转移部位骨化和骨矿物质密度(BMD)增加的病例尚未见报道。目前的研究显示了一名65岁的肺腺癌且腰椎和股骨发生骨转移的患者。用ZA处理并照射骨转移部位后,骨转移部位的骨化和BMD增加。尽管有骨转移,该患者仍能够维持正常的生活方式超过两年。因此,由于已证明使用ZA治疗可以改善患者的生活质量,因此医师应考虑这种治疗策略,尤其是对于承重骨骼转移的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号